SAB Biotherapeutics (SABS) Expected to Announce Earnings on Friday

Key Points

• Q1 2026 earnings due May 8 (pre-market) — SAB Biotherapeutics is set to report results on Friday, May 8, with analysts forecasting EPS of ($0.2125) and revenue of $0.125M; the company’s earnings call is scheduled for May 7 at 6:00 PM ET.
• Recent results and outlook remain challenged: the company missed last quarter’s EPS (reported ($0.46) vs. consensus ($0.16)), and analysts project roughly ($1) EPS for the current fiscal year and $0 EPS for the next year.
• SABS trades around $3.74 with a market cap of about $190.6M, a 12‑month range of $1.53–$6.60, very high liquidity (current and quick ratios of 9.46) and low leverage (debt/equity 0.02); consensus analyst rating is a Moderate Buy with an average price target of $10.50 amid mixed individual ratings.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) is expected to post its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect the company to announce earnings of ($0.2125) per share and revenue of $0.1250 million for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 6:00 PM ET.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last released its earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.30). On average, analysts expect SAB Biotherapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $3.74 on Friday. The company has a current ratio of 9.46, a quick ratio of 9.46 and a debt-to-equity ratio of 0.02. SAB Biotherapeutics has a 12-month low of $1.53 and a 12-month high of $6.60. The company has a market cap of $190.56 million, a price-to-earnings ratio of -1.61 and a beta of 0.60. The stock has a 50 day simple moving average of $3.87 and a 200-day simple moving average of $3.74.

Analysts Set New Price Targets

SABS has been the subject of a number of recent analyst reports. Rodman & Renshaw began coverage on SAB Biotherapeutics in a report on Thursday, April 2nd. They issued a "buy" rating and a $13.00 target price for the company. HC Wainwright dropped their target price on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday, March 10th. Zacks Research cut SAB Biotherapeutics from a "hold" rating to a "strong sell" rating in a report on Thursday, March 12th. UBS Group began coverage on SAB Biotherapeutics in a research note on Wednesday, January 7th. They issued a "buy" rating and a $7.00 price objective for the company. Finally, Chardan Capital lifted their price objective on SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, SAB Biotherapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $10.50.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of institutional investors have recently made changes to their positions in the stock. State of Wyoming acquired a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at $34,000. State Street Corp purchased a new position in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $49,000. ADAR1 Capital Management LLC purchased a new position in shares of SAB Biotherapeutics during the third quarter valued at approximately $30,000. Dimensional Fund Advisors LP purchased a new position in shares of SAB Biotherapeutics during the third quarter valued at approximately $32,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $74,000. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.